PharmaShots Weekly Snapshots (May 13 – May 17, 2024)

Share this

PharmaShots Weekly Snapshots (May 13 – May 17, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:


BMS Reports the Updated Data from P-III (CheckMate -73L) Study of Opdivo for Non-Small Cell Lung Cancer

Read More: BMS                                                                                     

HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China

Read More: HUTCHMED                               

HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma

Read More: HUTCHMED                                                                                            

Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease

Read More: Ocugen                                                                            

Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes

Read More: Roche                                                                

Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes

Read More: Eli Lilly                                                                                                  

BMS Reports Results from the P-III (POETYK PSO) Long-Term Extension Study of Sotyktu for Treating Plaque Psoriasis

Read More: BMS                                                                                          

HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

Read More: HUTCHMED                                                                                    


Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)

Read More: Regeneron & Sanofi                                                                      

Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)

Read More: Zai Lab                                                                                                     

Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

Read More: Meru                                                                  

Roche Receives the US FDA’s Approval for HPV Self-Collection Solutions for Cervical Cancer

Read More: Roche                                                                                               

The US FDA Rejects Dynavax’ Four-Dose Heplisav-B Regimen for Adults on Hemodialysis

Read More: Dynavax                                                                                           

BMS Reports the US FDA’s Accelerated Approval of Breyanzi for Treating Follicular Lymphoma (FL)

Read More: BMS                                                                                           

Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer

Read More: Amgen                 


Fulcrum Therapeutics Partners with Sanofi to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

Read More: Fulcrum Therapeutics & Sanofi                                                        

Takeda and AC Immune Collaborate for ACI-24.060 to Treat Alzheimer’s Disease

Read More: Takeda & AC Immune                                                                           

AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Next-Generation Therapies for Psychiatric Disorders

Read More: AbbVie & Gilgamesh Pharmaceuticals                                             

Sol-Gel Technologies and Beimei Pharma Collaborate to Commercialize Twyneo for Treating Acne Vulgaris

Read More: Sol-Gel Technologies & Beimei Pharma                                         


QIAGEN’s QIAstat-Dx Respiratory Syndromic Testing Panel Gains the US FDA’s Clearance to Diagnose Upper Respiratory Infections

Read More: QIAGEN                                                                                              

Profound Medical’s Contouring Assistant AI Module Gains the US FDA’s Approval for Creating Automated TULSA Treatment Plan

Read More: Profound Medical                                                                             

Atraverse Medical Reports the US FDA’s Clearance of Hotwire Left Heart Access Device

Read More: Atraverse Medical                                                                     

Karius Reports the US FDA’s Breakthrough Device Designation for its Karius Test to Diagnose Infectious Disease

Read More: Karius                                                                                                 


Johnson & Johnson to Expand its Dermatology Portfolio Through the Acquisition of Proteologix

Read More: Johnson & Johnson                                                                              


Merck Animal Health to Feature Innovative Solutions Focusing Ruminant Health at the World Buiatrics Congress 2024

Read More: Merck Animal Health                                                                     

Boehringer Ingelheim Introduces Bultavo 3 Vaccine Against Bluetongue Virus Serotype 3 for Sheep and Cattle

Read More: Boehringer Ingelheim                                                                             

Ainos to Commence Clinical Trial of Veldona-Based Drugs for Treating Pet Disease

Read More: Ainos                           



Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)

Read More: Boehringer Ingelheim & Quallent Pharmaceuticals                    


AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

Read More: AstraZeneca                                                                                       


Azitra Highlights Preclinical Results and P-Ib Clinical Design of ATR-12 for Netherton Syndrome at the ASGCT 2024

Read More: Azitra        

Related Post:- PharmaShots Weekly Snapshots (May 06 – May 10, 2024)                                                                   

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions